Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2025-02-14 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
江苏四环生物股份有限公司公司章程（2025年2月）
Governance Information Classification · 95% confidence The document is a detailed company charter or articles of association for 江苏四环生物股份有限公司 (Jiangsu Sihuan Bioengineering Co., Ltd.). It covers comprehensive governance topics such as company structure, shareholder rights, board and management roles, share issuance and transfer, shareholder meetings, voting procedures, and other corporate governance rules. It does not contain financial statements, audit opinions, earnings data, or any report publication announcements. Instead, it is a governance document outlining internal rules and procedures for the company and its shareholders. Therefore, the document best fits the category of Governance Information (CGR). The document length (15,000 characters) and content confirm it is a full governance report, not a brief announcement or a proxy statement.
2025-02-14 Chinese
江苏四环生物股份有限公司详式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled '详式权益变动报告书' which translates to 'Detailed Equity Change Report'. It is issued by 江苏四环生物股份有限公司 and details a significant change in shareholding by 福建碧水农业投资有限公司 acquiring 27.78% of the company's shares. The document includes extensive information about the equity change, the parties involved, their backgrounds, financial data, and the purpose and plans related to the equity change. It references relevant Chinese securities laws and regulations governing equity changes and disclosures. This type of document corresponds to a Major Shareholding Notification, which reports changes in significant share ownership levels crossing thresholds. The document is lengthy (15,000 characters) and contains detailed substantive information, not just an announcement or certification. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2025-01-22 Chinese
开源证券股份有限公司关于江苏四环生物股份有限公司详式权益变动报告书之财务顾问核查意见
Major Shareholding Notification Classification · 95% confidence The document is titled as a "详式权益变动报告书" which translates to a "Detailed Equity Change Report." It includes extensive sections on the verification and audit opinions by a financial advisor regarding an equity change transaction involving a listed company (江苏四环生物股份有限公司). The content covers detailed information about the equity change, the parties involved, legal and regulatory compliance, financial status, and the transaction process including judicial auction details. The document is lengthy (15,000 characters) and contains substantive financial and legal information related to a change in shareholding or equity control. This matches the definition of a Major Shareholding Notification (MRQ), which involves notifications of changes in significant share ownership levels crossing thresholds. The document is not an announcement of a report but the report itself, and it is not a general regulatory filing or a report publication announcement. Therefore, the appropriate classification is MRQ with high confidence.
2025-01-22 Chinese
江苏四环生物股份有限公司关于股东权益变动暨控制权变更的提示性公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding a change in shareholder equity and control of the company 江苏四环生物股份有限公司. It details the transfer of shares through a judicial auction, the new controlling shareholder, and the actual controller. It includes specific dates, shareholding percentages before and after the change, and legal confirmations of the transfer. The document does not contain financial statements, audit information, or detailed financial performance data. It is not a report but an announcement about a significant change in shareholding and control. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels and control changes. The document length is 2359 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is MRQ with high confidence.
2025-01-22 Chinese
江苏四环生物股份有限公司2024年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2024 annual performance forecast (业绩预告) for Jiangsu Sihuan Bio, covering the full fiscal year 2024 (Jan 1 to Dec 31). It provides estimated financial results including expected losses, revenue, and net profit figures. It explicitly states that the data is preliminary and unaudited, with final audited results to be disclosed in the 2024 annual report. The document also mentions potential delisting risk if audited results confirm losses. The document length is short (1402 characters) and it is a forward-looking earnings forecast rather than a full financial report or audited statement. This type of document is best classified as an Earnings Release (ER), which is the initial announcement of periodic financial results or forecasts with key highlights only, not a full annual report or audit report. FY 2024
2025-01-21 Chinese
江苏四环生物股份有限公司关于公司股票交易可能被实施退市风险警示的提示性公告
Delisting Announcement Classification · 95% confidence The document is a short announcement (1025 characters) from Jiangsu Sihuan Bio Co., Ltd. regarding the potential risk of the company's stock being subject to a delisting risk warning based on the Shenzhen Stock Exchange listing rules. It references the 2024 annual audited financial results and the possibility of a risk warning after the 2024 annual report is disclosed. The document does not contain actual financial statements or detailed financial data but is a forward-looking risk warning notice. It also states that the audited financial data will be disclosed in the formal 2024 annual report later. This fits the definition of a Delisting Announcement (DLST) as it is an official notice about the potential removal or risk warning of the company's stock from the exchange. The document is not the annual report itself, nor a report publication announcement, but a regulatory announcement about delisting risk.
2025-01-21 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.